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Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal 
management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient. Re-
cent introduction of novel insulin preparations, technological advances in insulin delivery and glucose monitoring, such as con-
tinuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring and improved understanding of the detrimen-
tal efects of hypoglycaemia and hyperglycaemia ofer new opportunities and perspectives in T1DM management. Evidence from 
clinical trials suggests an important role of structured patient education. Our eforts should be aimed at improved metabolic con-
trol with concomitant reduction of hypoglycaemia. Despite recent advances, these goals are not easy to achieve and can put sig-
niicant pressure on people with T1DM. he approach of physicians should therefore be maximally supportive. In this review, we 
provide an overview of the recent advances in T1DM management focusing on novel insulin preparations, ways of insulin ad-
ministration and glucose monitoring and the role of metformin or sodium-glucose co-transporter 2 inhibitors in T1DM manage-
ment. We then discuss our current understanding of the efects of hypoglycaemia on human body and strategies aimed at mitigat-
ing the risks associated with hypoglycaemia. 
Keywords: Artiicial pancreas device systems; Blood glucose self-monitoring; Continuous glucose monitoring; Continuous sub-
cutaneous insulin infusion; Diabetes mellitus, type 1; Hypoglycemia; Impaired awareness of hypoglycaemia; Severe hypoglycae-
mia; Structured education
Corresponding author: Simon R. Heller  https://orcid.org/0000-0002-2425-9565 
Department of Oncology and Metabolism, University of Sheield, Medical School, Beech 
Hill Rd, S10 2 RX, Sheield, UK 
E-mail: s.heller@sheield.ac.uk
*Ahmed Iqbal and Peter Novodvorsky contributed equally to this study as irst authors.
Received: Jan. 25, 2018; Accepted: Jan. 31, 2018
INTRODUCTION
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune con-
dition resulting in absolute shortage of pancreatic insulin pro-
duction. Regular and life-long insulin administration is there-
fore necessary to prevent hyperglycaemia, metabolic decom-
pensation and life-threatening diabetic ketoacidosis (DKA). 
According to the International Diabetes Federation (IDF), 
there were approximately 425 million people living with diabe-
tes worldwide in 2017, out of which 5% to 10% are estimated to 
have T1DM (42.5 to 95 million) [1]. Management of T1DM 
requires good understanding of this condition by patients and 
their physicians. At the same time, it imposes signiicant inan-
cial costs on health systems worldwide. Optimal management 
of T1DM leading to good metabolic control with prevention of 
micro- and macrovascular complications with concomitant 
avoidance of hypoglycaemia is therefore of signiicant social 
and economic importance.
Publication of the landmark study Diabetes Control and 
Complications Trial (DCCT) in 1993 provided clear evidence 
that intensive therapy consisting of insulin administration by 
three or more daily injections or by a pump with self-monitor-
ing of blood glucose (SMBG) 4 times/day or more and fre-
quent insulin dose adjustments reduced risk of microvascular 
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complications in comparison to conventional therapy of that 
time (one to two insulin injections/day, daily self-monitoring 
of urine or blood glucose [BG] and education about diet and 
exercise) [2]. he incidence of severe hypoglycaemia (SH) was 
approximately three times higher in the intensive group, how-
ever [2]. Intensive therapy with frequent SMBG, patient educa-
tion and avoidance or minimising occurrence of hypoglycae-
mia have since then become the pillars of modern T1DM 
management. 
In this review, we provide an overview of the recent advances 
in T1DM management focusing on novel insulin preparations, 
ways of insulin administration and glucose monitoring and the 
role of metformin or sodium-glucose co-transporter 2 (SGLT2) 
inhibitors in T1DM management. We then discuss our current 
understanding of the efects of hypoglycaemia on human body 
and the ways how to prevent or minimise its occurrence.
INSULIN PREPARATIONS AND 
ADMINISTRATION
Insulin administration represents the mainstay of T1DM treat-
ment. he purpose of insulin administration is to prevent the 
development of DKA due to the absolute shortage of intrinsic 
insulin production and to maintain BG levels within the physi-
ologic range. Insulin administration should thus ideally pre-
vent, or at least delay development of micro- and macrovascu-
lar complications of hyperglycaemia and, at the same time, 
should cause as little hypoglycaemia as possible. To achieve 
this, pharmacokinetic and pharmacodynamic properties of 
administered insulin should ideally, mimic those of physiolog-
ic insulin release from pancreatic E-cells in healthy individuals 
in whom basal continuous insulin secretion into the portal 
vein together with super-added peak insulin secretions closely 
following the rise in plasma glucose concentration 30 to 60 
minutes ater eating can be observed [3]. his has proven to be 
a challenging task as the physiological mechanisms controlling 
glucose metabolism are extremely complex. hus, current in-
sulin formulations and modes of delivery are unable to fully 
reproduce the physiology of the E-cell [4]. Since the discovery 
of insulin in the 1920s [5] remarkable steps towards achieving 
this goal have been made, but there is still a long way to go. he 
currently available insulin preparations in the UK, as listed in 
the “British National Formulary (BNF)” at the time of writing 
of the manuscript (December 2017), together with their chem-
ical structure and action proiles are listed in Table 1. Histori-
cally, animal insulins made from bovine or porcine pancreatic 
extracts were used irst, since the 1970s prepared as a ‘mono-
component insulin,’ but their use has been complicated by al-
lergic reactions caused by impurities, other immunogenicity 
problems and variable rates of absorption. Interestingly, there 
is still a minority of patients who use animal insulins at pres-
ent. heir numbers are likely to decrease in the near future as 
the manufacturer of the Hypurin® Bovine (Wockhardt UK 
Ltd., Wrexham, UK) has recently announced the discontinua-
tion of bovine insulin in the UK by the end of 2017. he pro-
duction of porcine insulin is being continued, however. The 
amino acid sequence of insulin was reported in 1955 [6] and 
insulin was the irst therapeutic protein to be produced by re-
combinant DNA technology in late 1970s [7]. Commercial 
production of human insulin in the early 1980s enabled pro-
duction of synthetic human insulin in virtually unlimited 
quantities and in a cost-efective way [8]. he tendency of hu-
man soluble insulin to aggregate into dimers and hexamers in 
higher concentrations with resulting delay in release of insulin 
monomers into the bloodstream from the subcutaneous depot 
has important consequences for its pharmacokinetic and phar-
macodynamic properties and has prompted the development 
of rapid-acting insulin analogues [9]. he irst rapid-acting in-
sulin analogue, insulin lispro (Humalog®; Elly Lilly Ltd., India-
napolis, IN, USA), was introduced in the USA in 1996 and the 
introduction of insulin aspart (Novorapid®; Novo Nordisk 
Ltd., Bagsværd, Denmark) and glulisine (Apidra®; Sanoi, Par-
is, France) followed soon after. Their pharmacokinetic and 
pharmacodynamic proiles show more rapid rise ater injec-
tion to higher plasma insulin levels together with more rapid 
fall of their concentration in comparison to regular insulin [10] 
resulting in improved post-prandial plasma glucose (PPG) 
profiles [11]. Initial trials comparing the use of rapid-acting 
analogues versus regular insulin (combined with intermediate 
insulins isophane or ultralente since long-acting insulin ana-
logues were introduced some years later) showed a signiicant 
reduction of overall rates of hypoglycaemia and SH [12], with 
the most prominent reduction observed in episodes at night in 
those with tight metabolic control (glycosylated hemoglobin 
[HbA1c] <7.5%) [13]. he latest step towards the goal of repli-
cating endogenous prandial insulin secretion proiles is the in-
troduction of faster insulin aspart (Fiasp®; Novo Nordisk Ltd.), 
a formulation of insulin aspart with additional L-arginine and 
niacinamide (vitamin B3) that promote stability and faster for-
mation of insulin aspart monomers ater subcutaneous injec-
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tion [14]. In a 26-week, double-blinded, treat-to-target trial 
(ONSET 1), mealtime Fiasp® significantly reduced HbA1c 
versus insulin aspart with estimated treatment difference 
(ETD) –0.15% (95% conidence interval [CI], –0.23 to –0.07; 
P=0.0003) and also significantly reduced post-PPG incre-
ments at 1 hour (ETD, –1.18 mmol/L; 95% CI, –1.65 to –0.71; 
P<0.0001) and at 2 hours (ETD, –0.67 mmol/L; 95% CI, –1.29 
to –0.04; P=0.0375) without increasing risk of overall hypogly-
caemia [15]. BioChaparone insulin lispro (Adocia, Lyon, 
France) uses polysaccharides that can be modiied with amino 
Table 1. he list of currently available insulin preparations in the UK (December 2017)
Origin Type
Name of insulin/Brand name 
(manufacturer)
Chemical structurea
Onset of 
efect
Peak of 
efect
Duration 
of efect
Bovine Neutral insulin 
(quick acting)
Hypurin Bovine Neutral® (Wockhardt 
UK Ltd.)
Ala → hr at A8 
Val → Ile at A10
Ala → hr at B30 
30 min 3–4 hr 8 hr
Bovine Intermediate Hypurin Bovine Isophane® (Wockhardt 
UK Ltd.)
Protamine suspension 4–6 hr 8–14 hr 16–20 hr
Bovine Long acting Hypurin Bovine Protamine Zinc® or 
Hypurin Bovine Lente® (Wockhardt 
UK Ltd.)
Protamine or zinc suspension 4–6 hr 8–14 hr 16–20 hr
Porcine Neutral insulin Hypurin Porcine Neutral® (Wockhardt 
UK Ltd.)
Ala → hr at B30 30 min 3–4 hr 8 hr
Porcine Intermediate Hypurin Porcine Isophane® (Wockhardt 
UK Ltd.)
Protamine suspension 4–6 hr 8–14 hr 16–20 hr
Porcine Pre-mixed  
(biphasic)
Hypurin Porcine Mix 30/70® (Wock-
hardt UK Ltd.)
Neutral and protamine suspension
Human Neutral insulin 
(quick acting)
Actrapid® (Novo Nordisk Ltd.)
Humulin S® (Elly Lilly Ltd.)
Insuman Rapid® (Sanoi)
– 30 min 2–4 hr 6–8 hr
Human Intermediate Insulatard® (Novo Nordisk Ltd.)
Humulin I® (Elly Lilly Ltd.)
Insuman Basal® (Sanoi)
– 2–4 hr 4–8 hr 14–16 hr
Human Pre-mixed  
(biphasic) neu-
tral/Isophane
Humulin M3® (Elly Lilly Ltd.)
Insuman Comb 15®/25®/50® (Sanoi)
Neutral insulin and insulin prot-
amine suspension
Preparation 
speciic
Analogues Rapid-acting Aspart/Novorapid® (Novo Nordisk Ltd.)
Lispro/Humalog® U100 or U200 (Elly 
Lilly Ltd.)
Glulisine/Apidra® (Sanoi)
Faster aspart/Fiasp® (Novo Nordisk 
Ltd.)
Pro → Asp at B28 
Pro at B28 and Lys at B29
Asn → Lys at B3 and Glu → Lys at 
B29
Pro → Asp at B28 with added L-argi-
nine and niacinamide (vitamin 
B3)
5–15 min
4 min
1–1.5 hr 4–6 hr
Analogues Long-acting Detemir/Levemir® (Novo Nordisk Ltd.)
Glargine/Lantus® (Sanoi) or Abasaglar® 
(Elly Lilly Ltd.)
Glargine U300/Toujeo® (Sanoi)
Degludec/Tresiba® U100 or U200 
(Sanoi)
No hr at B30, C14 fatty acid to B29 
Asn → Gly at A21 +2x Arg to B31/
B32 
No hr at B30 C16 fatty acid to B29 
1–4 hr
1–4 hr
1–4 hr
– 20–24 hr
18–26 hr
Up to 42 hr
Analogues Pre-mixed  
(biphasic)  
rapid acting/
intermediate
NovoMix 30® (Novo Nordisk Ltd.)
Humalog Mix 25®/50® (Elly Lilly Ltd.) 
Aspart and aspart protamine sus-
pension
Lispro and lispro protamine suspen-
sion
Preparation 
speciic
aCompared to structure of human insulin molecule.
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acids to facilitate its absorption into blood circulation and clin-
ical trials of this formulation are currently in progress.
he introduction of long-acting (basal) insulin analogues re-
lected the drive to goal develop a ‘peakless’ continuous insulin 
action proile which would mimic basal insulin secretion ob-
served in healthy individuals. he available intermediate insu-
lins (isophane and lente/ultralente) exhibited a peak glucose 
lowering efect several hours into their onset of action with in-
creased risk of hypoglycaemia, particularly at night. his was 
compounded by a considerable day-to-day variability of their 
glucose lowering action. Insulin glargine/Lantus® (Sanofi), 
since 2015 also produced by Elly Lilly (Abasaglar®), was irst 
introduced in 2000 and was followed by insulin detemir/
Levemir® (Novo Nordisk Ltd.) in 2005. Basal analogues were 
shown to have a latter action proile and a more predictable 
efect, longer duration of action with resulting lower frequency 
of injections. his led to signiicantly fewer hypoglycaemic epi-
sodes in comparison to intermediate insulin although severe 
episodes were generally not reduced signiicantly, perhaps be-
cause those at greatest risk of hypoglycaemia were generally 
excluded from clinical trials [16]. It is noteworthy that a recent 
trial which compared rates of hypoglycaemia using insulin an-
alogues (insulin aspart and levemir) to human insulin in pa-
tients at high risk of hypoglycaemia using a crossover design 
was able to show a signiicant reduction in rates of SH, particu-
larly during the night [17]. More recently, two longer acting in-
sulin analogues, glargine U300/Toujeo® (Sanofi) and insulin 
degludec/Tresiba® have been introduced. he development of 
glargine U300 adopts the principle that glargine at higher con-
centration, forms subcutaneous crystals from which insulin is 
absorbed more slowly. Insulin degludec utilises a glutamic acid 
spacer to produce both a much slower degradation into insulin 
monomers. he results of head to head clinical trials between 
these two new insulins which have half-lives of over 24 hours 
are awaited. However, one recent clinical trial which adopted a 
double blind, randomized, cross-over design showed major re-
ductions in SH among individuals with T1DM particularly at 
night (SWITCH 1) [18] and similar results were observed in 
an identically designed trial in people with type 2 diabetes mel-
litus (T2DM)-SWITCH 2 trial [19]. 
he efect of insulin analogues on HbA1c reduction, as com-
pared with regular and intermediate insulins, in the case of 
T1DM (in T2DM as well) has been very modest, if any, with 
significant number of trials showing no improvement at all 
[20]. However, this in part is due to a treat-to-target design 
mandated by the regulatory authorities in insulin dosing algo-
rithms are used in both arms to achieve comparable fasting 
glucose targets are patients. Nevertheless, the higher cost of in-
sulin analogues, has contributed to an ongoing debate as their 
overall cost-efectiveness in diabetes management [20,21]. It is 
increasingly accepted; however, that the use of insulin ana-
logues in a form of a multiple daily insulin (MDI) regimen or 
as a continuous subcutaneous insulin infusion (CSII) is the op-
timal management strategy in people with T1DM [20,22,23].
MODES OF INSULIN DELIVERY
Currently, the most widespread mode of insulin delivery is via 
a subcutaneous injection by the help of an insulin pens and 
single-use thin needles. For this purpose, manufacturers either 
provide pre-illed single-use disposable pens or insulin pens 
with replaceable cartridges. he use of disposable syringes and 
insulin vials has been nearly completely abolished across the 
Europe and also in North America.
CSII, also known as an ‘insulin pump’ was introduced into 
the clinical practice in the early 1980s. CSII uses a portable 
electromechanical pump continuously infusing rapid-acting 
insulin into the subcutaneous tissue at pre-selected rates (‘basal 
rate’) mimicking the basal insulin secretion in non-diabetic in-
dividuals with patient-activated insulin boluses delivered with 
meals. In a meta-analysis of 12 randomised controlled trials 
(RCTs) comparing CSII versus MDI regimens, CSII was 
shown to reduce mean HbA1c by approximately 0.51% as well 
as BG variability and this was achieved by an average reduc-
tion of total insulin dose of 14% [24]. Another meta-analysis of 
22 trials which included patients with high baseline rates of SH 
showed that occurrence of SH was reduced more than four-
fold during CSII in comparison with MDI (rate ratio of 4.19; 
95% CI, 2.86 to 6.13) with the greatest reduction seen in those 
with the highest initial rates of SH [25]. It has to be mentioned; 
however, that none of the RCTs reporting benefit included 
long-acting insulin analogues in the MDI arm. he beneits of 
CSII in relation to the reduction of HbA1c and rates of hypo-
glycaemia seem to persist over several years as a recent study 
has indicated [26]. The above benefits of CSII have to be 
matched against significantly higher costs in comparison to 
MDI regimens and hence most health systems recommend the 
use of CSII only once adequate metabolic control can’t be 
achieved with MDI regimen or in cases of troublesome SH. On 
the other hand, the HypoCOMPaSS (Comparison of Opti-
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mised MDI versus Pumps with or without Sensors in Severe 
Hypoglycemia) trial with a 2×2 factorial design examined the 
efect of CSII versus MDI regimen (using long and rapid-act-
ing insulin analogues) and continuous glucose monitoring 
(CGM) versus SMBG on the restoration of hypoglycaemia 
awareness and decrease of SH as well as overall biochemical 
hypoglycaemia [27]. All participants received comparable edu-
cation, support and identical therapeutic targets aiming at rig-
orous avoidance of hypoglycaemia. Ater 24 weeks, more than 
10-fold decrease in incidence of SH, decrease in occurrence of 
overall biochemical hypoglycaemia without deterioration in 
HbA1c and improvement in hypoglycaemia awareness were 
observed. Interestingly, no statistically signiicant diferences 
in rates of SH or awareness improvement were observed com-
paring CSII versus MDI or CGM versus SMBG. his clearly 
highlights the essential role of education and patient support 
in management of SH and impaired awareness of hypoglycae-
mia (IAH) [27]. 
USE OF METFORMIN IN T1DM
Metformin, a biguanide commonly used in management of 
T2DM has been used of-label in people with T1DM in an at-
tempt to reduce efective insulin dose requirements and associ-
ated weight gain [28]. he current National Institute for Health 
and Care Excellence (NICE) guidelines for management of 
T1DM recommend considering metformin in adults with 
T1DM and a body mass index (BMI) ≥25 kg/m2 who ‘want to 
improve glucose control while minimising their efective insu-
lin dose’ [22]. American Diabetes Association (ADA) also rec-
ommend adding metformin to insulin therapy which may re-
duce insulin requirements and improve metabolic control in 
overweight or obese people with poorly controlled T1DM [23]. 
It is noteworthy that these recommendations are based on rela-
tively limited amount of evidence. A meta-analysis undertaken 
by Lund et al. [29] in 2010 (only ive trials included) reported a 
signiicant reduction of insulin dose (6.6 units/day, P<0.001), 
but changes in HbA1c were inconsistent. A recent trial report-
ed that adding metformin (1g twice daily) to titrated insulin 
therapy (target HbA1c 53 mmol/mol) in people with T1DM 
aged 40 years or older and with three or more cardiovascular 
(CV) risk factors for duration of 3 years resulted in signiicant 
reduction of progression of caroT1DM artery intima-media 
thickness, a surrogate marker for progression of atherosclero-
sis (P=0.0093) [30]. his approach also led to signiicant falls 
in low density lipoprotein cholesterol (–0.13 mmol/L, 
P=0.012), sustained weight reduction (–1.17 kg, P<0.0001) 
and lower HbA1c at 3 months by 2.6 mmol/mol (P<0.001), al-
though this was not sustained [30]. hese data while interest-
ing, are arguably insuicient to recommend a change in prac-
tice, in the absence of a large trial which includes outcomes of 
more relevance to patients. his leaves clinicians to use their 
clinical judgement based on currently existing evidence when 
considering initiation of metformin in people with T1DM. 
USE OF SGLT2 INHIBITORS IN T1DM
Inhibitors of SGLT2 are the newest class of drugs approved for 
treatment of T2DM [31]. SGLT2 inhibition reduces renal tu-
bule glucose reabsorption by promoting urinary glucose excre-
tion. The three currently available SGLT2 inhibitors—dapa-
gliflozin, empagliflozin, and canagliflozin result in improve-
ments of metabolic control and were also shown to cause 
weight and blood pressure reduction [31]. In addition, two 
large CV outcome trials have shown their positive efects on 
hard CV endpoints—EMPA-REG (Empaglilozin Cardiovas-
cular Outcome Event Trial in Type 2 Diabetes Mellitus Pa-
tients) for empaglilozin [32] and the CANVAS (Canaglilozin 
Cardiovascular Assess ment Study) trial for canaglilozin [33] 
but in patients with T2DM at increased CV risk. Clearly, the 
insulin-independent mode of action of SGLT2 inhibitors 
might also beneit individuals with T1DM, but the initial ex-
citement was set back by the reports of euglycaemic DKA both 
in people with T2DM and T1DM [34]. In the recently pub-
lished phase 3 trial DEPICT-1 (Dapaglilozin Evaluation in Pa-
tients with Inadequately Controlled Type 1 Diabetes), dapa-
glilozin, when given as an oral adjunct to adjustable insulin in 
patients with inadequately-controlled T1DM demonstrated 
signiicant reductions from baseline in HbA1c, body weight, 
and also lowered total daily insulin dose at 24 weeks at both 
the 5 and 10 mg dose compared to placebo whilst the inci-
dence of hypoglycaemia, SH and adjudicated ketoacidosis did 
not difer signiicantly between both treatment arms and the 
placebo arm [35]. Participants in this study were provided with 
a combined BG and ketone meter and were asked to measure 
BG four times a day and ketonaemia whenever BG readings 
were consistently elevated. Participants were also instructed to 
reduce insulin doses by no more than 20% on initiation of the 
study medication and then subsequently to up-titrate insulin 
doses back to baseline [36]. A 26-week extension phase of this 
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trial is currently in progress. Sotaglilozin is a novel inhibitor of 
SGLT1 and SGLT2. SGLT1 inhibition in the intestine reduces 
glucose absorption in proximal intestine resulting in signii-
cant blunting and delay of post-prandial hyperglycaemia [37]. 
Results of a recently published phase 3 double-blinded RCT 
show that sotaglilozin versus placebo added to insulin therapy 
for 24 weeks in people with T1DM resulted in signiicantly in-
creased number of participants who achieved HbA1c levels 
<7.0% (28.6% vs. 15.2%, P<0.001) with similar rates of SH in 
both groups [37]. Sotagliflozin use versus placebo was also 
linked with signiicantly higher reduction of weight (–2.98 kg), 
systolic blood pressure (–3.5 mm Hg) and mean daily bolus of 
insulin (–2.8 units/day) (P<0.002 for all comparisons). The 
rate of DKA was higher in the sotagliflozin group (3.0% vs. 
0.6%). Mean baseline BMI in the sotagliflozin group was 
28.29±5.13 and in the placebo group 28.10±5.18 [37].
hese results suggest that SGLT2/SGLT1 inhibitors may be 
an appropriate adjunct to insulin in people with T1DM who 
monitor BG regularly, have the availability to monitor ketonae-
mia in home environment and have good understanding of 
early signs of ketoacidosis. he risk of DKA will need to be bal-
anced by the potential beneits. More research is required, par-
ticularly as there is emerging evidence that these agents may 
provide protection from long-term renal disease. 
BLOOD GLUCOSE MONITORING
BG monitoring requires individuals with diabetes to apply in-
ger-prick capillary samples to reagent test strips which are then 
inserted into portable meters (SMBG) and was originally in-
troduced into clinical practice in 1978 [38]. Initially indicated 
for use in pregnancy, SMBG spread widely and has become an 
essential component of lexible intensiied insulin therapy pio-
neered by Muhlhauser et al. [39] in the early 1980s. he ap-
proach was reinforced by the publication of the DCCT trial in 
1993 [2]. SMBG is now an integral part of modern T1DM 
management included as part of structured education courses, 
such as dose adjustment for normal eating (DAFNE) [40] and 
others. SMBG is usually undertaken pre-meal and before bed 
to guide insulin dosing based on carbohydrate intake. In addi-
tion to detecting hypo- or hyperglycaemia, serial SMBG read-
ings inform trends and luctuations in BG and help individuals 
to achieve glucose targets and optimise metabolic control. All 
modern BG meters are plasma-calibrated (BG readings from 
plasma are up to 14% higher compared to whole-blood read-
ings due to lower glucose concentrations in erythrocytes), use 
a minimal amount of capillary blood (<1 µL) and have a 
memory with a capacity to store several hundreds of BG read-
ings. Most BG meter manufacturers provide sotware enabling 
BG data download into a PC or mobile device where a more 
detailed statistical analysis can be performed as detailed below. 
here is evidence available suggesting a strong association be-
tween increased frequency of SMBG and improved metabolic 
control, however the available information needs to be used ef-
fectively in diabetes management as the act of performing 
SMBG alone is not directly related to improved HbA1c [41]. 
Some new BG meters can also measure concentrations of plas-
ma ketone bodies (E-hydroxybutyrate). Early detection of in-
creased ketonaemia by the patient outside the hospital, for ex-
ample in cases of intercurrent illness, can lead to timely treat-
ment preventing the development of full-blown DKA and 
need for hospital admissions. 
Systems which monitor glucose every few minutes (CGM) 
have moved from the research to the clinical arena in the last 
decades [42]. CGM use has steadily increased as accuracy and 
costs have fallen although high running costs and resulting re-
imbursement issues have limited its widespread use in in most 
healthcare systems. CGM devices monitor interstitial, rather 
than plasma glucose levels (IG) in regular closely spaced time 
intervals, mostly every 5 to 10 minutes. IG data is then trans-
mitted from a sensor to a reader with a monitor where it can 
be accessed in a graphical or numerical format. In clinical 
practice, real-time CGM usually displays real-time IG readings 
together with trends, rate of change and ofer an option to set 
alarms for high and low readings at pre-set thresholds. This 
permits immediate action in cases of impeding hypo- or hy-
perglycaemia. The physiological lag time of 4 to 10 minutes 
between changes in plasma glucose and IG concentrations [43] 
is particularly relevant when BG is changing rapidly, for exam-
ple during hypoglycaemia. RCTs have shown modest beneits 
of CGM versus SMBG in relation to HbA1c reduction in par-
ticipants who were generally experienced pump users [44,45]. 
Two recently published trials have also shown a clear beneit of 
CGM in this aspect in those using MDI. he open-label cross-
over GOLD trial examined the efect of 26-week long use of 
CGM versus SMBG in 161 participants with T1DM on MDI 
(mean baseline HbA1c 8.6% or 70 mmol/mol) and found a 
signiicant fall in HbA1c linked with the use of CGM to 7.9% 
(63 mmol/mol) compared to a fall in the SMBG arm to 8.35% 
(68 mmol/mol) giving a mean difference of –0.4% (95% CI, 
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–0.57% to –0.29%) (4.7 mmol/mol; 95% CI, –6.3 to –3.1 
mmol/mol; P<0.001) [46]. Similarly, the DIA MOND (Multi-
ple Daily Injec tions and Continuous Glucose Monitoring in 
Diabetes) study reported a mean HbA1c fall from baseline of 
1.1% at 12 weeks and 1.0% at 24 weeks of CGM use, signii-
cantly more than the diference of 0.5% at 12 and 0.4% at 24 
weeks seen in the control (SMBG) group (repeated measures 
model P<0.001) [47]. hese trials also reported positive efect 
of CGM on the time spent in hypoglycaemia and prevention of 
hypoglycaemic episodes, and, in case of the GOLD study, also 
on incidence of SH [45-47]. he important prerequisite for the 
beneicial efects of CGM to manifest is good compliance with 
its use, in the above mentioned studies it neared 90% of the 
time. 
Sensor-augmented pump (SAP) therapy refers to a combi-
nation of a CGM and a CSII therapy which are integrated in a 
way that the insulin pump acts as a receiver of the CGM data 
sent to it wirelessly from the sensor by a transmitter. In SAP, 
CGM readings do not inluence the rate of insulin delivery by 
the insulin pump per se and it is up to the user to adjust insulin 
rates based on the available CGM data. Several studies have re-
ported a clear beneit of SAP versus CSII alone or MDI (with 
SMBG) on metabolic control, but this required good sensor 
compliance, at least 70% of the time. he RealTrend trial ex-
amined the efect of SAP versus CSII alone treatment modali-
ties in patients with suboptimal metabolic control (HbA1c 
≥8.0%) who have previously been on MDI regimen [48]. Ater 
6 months, HbA1c improved signiicantly in both groups (SAP 
group −0.81%±1.09%, P<0.001; CSII group −0.57%±0.94%, 
P<0.001), with no signiicant diference between the groups. 
However, when only those with sensor compliance of ≥70% in 
the SAP group were considered, HbA1c improvement was sig-
nificantly greater in the SAP group (P=0.004) (SAP group 
−0.96%±0.93%, P<0.001; CSII group −0.55%±0.93%, P< 
0.001) [48]. 
SAP systems with the low glucose suspend (LGS) feature, 
like the MiniMedTM Paradigm VeoTM (Medtronic Inc., Watford, 
UK), allow for a temporary suspension of insulin delivery 
(usually for up to 2 hours) when IG level falls below a pre-de-
ined threshold value. he ASPIRE (Automation to Simulate 
Pancreatic Insulin Response) trial showed a clear benefit of 
SAP with LGS versus SAP alone in reduction of nocturnal hy-
poglycaemia. Nocturnal hypoglycaemic events occurred 
31.8% less frequently and the mean area under the curve for 
nocturnal hypoglycaemia was 37.5% lower in the LGS group 
(both P<0.001) with comparable changes in HbA1c. Rates of 
SH were also reduced [49]. In a RCT published by Ly et al. [50], 
use of SAP with LGS for 6 months resulted in decrease of SH 
from 175 events per 100 patient-months to 35 and in the SAP 
only group the decrease in the event rate was from 28 to 16. 
Despite randomisation, significant difference in the baseline 
prevalence of hypoglycaemia between the study groups existed 
in this study. Nevertheless, the results are certainly promising.
The MiniMedTM 640G Insulin Pump System (Medtronic 
Inc.) with the SmartGuardTM technology is a next-generation 
LGS system enabling suspension of insulin delivery in re-
sponse to a predicted, rather than actual hypoglycaemic level. 
Insulin suspension is activated if IG is predicted to reach or fall 
below a pre-set low limit within next 30 minutes. Insulin deliv-
ery will automatically re-start 30 minutes later if IG at that time 
is above the pre-set limit and is predicted to remain above the 
low limit for subsequent 30 minutes. Initial observational stud-
ies indicate that this system could prevent a substantial num-
ber of hypoglycaemic episodes: 2,322 suspend-before-low 
events (2.1 per subject-day) in a group of 40 adults with T1DM 
were encountered and in 1,930 events (83.1%) subsequent IG 
levels did not reach the pre-set low limit meaning that hypo-
glycaemic episode was avoided, and this device seems to be 
well tolerated by its users [51]. he last step towards the ‘artii-
cial pancreas’ so far has been made with the introduction of 
the irst hybrid closed-loop system on the US market in 2017, 
the MiniMedTM 670G Insulin Pump System (Medtronic Inc.). 
his system, on top of the above listed features, combines the 
user-delivered pre-meal insulin boluses with the ability to au-
tomatically adjust basal insulin delivery every 5 minutes based 
on the IG readings [52]. Other more advanced closed-loop 
systems are being developed at present [53]. 
Another important development on the CGM market is the 
introduction of a first flash glucose monitoring system, the 
FreeStyle® Libre (FL; Abbott Diabetes Care, Maidenhead, UK). 
FL consists of a subcutaneous button-like sensor that measures 
IG every minute with a storage capacity of 8 hours of data and 
of a reader with a monitor. Swiping the reader over the sensor 
collects IG data at the moment of scanning plus up to 8 hours 
of prior readings every 15 minutes. Hence in order to get a 
continuous IG trace, the user is asked to swipe the reader at 
least once in every 8-hour time interval. FL is factory-calibrat-
ed and running costs are approximately half of those of current 
CGM devices. On the down side, given its character, it pro-
vides IG trends but no hypo/hyperglycaemia alarms can be set. 
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he accuracy of FL is comparable to currently used standard 
CGM devices, with mean absolute relative diference of 11.4%, 
as reported by the manufacturer and also in real-life settings 
with most accurate results measured with a sensor inserted in 
the upper arm [54]. FL has been shown to reduce the time 
spent in hypoglycaemia by 38% in a group of well controlled 
patients with T1DM (HbA1c ≤7.5%) and has been well toler-
ated by its users thus far [55,56]. It therefore represents an at-
tractive alternative to ‘classic’ CGM systems in certain, but not 
all clinical scenarios in T1DM management as well as in other 
indications for CGM use [57]. Table 2 provides a summary of 
the main features of currently available devices for BG/IG 
monitoring.
With increasing amounts of data available from frequent 
SMBG, but mainly with the introduction and wider use of CGM 
systems, a more complex and clinically relevant analysis of glu-
cose readings became possible. Indices such as glycaemic vari-
ability (assessed by coeicient of variation as a primary, or stan-
dard deviation [SD] as a secondary metric), time in range (time 
spent in an individual’s target glucose range) or ‘time in level 1 
or level 2 of hypo- or hyperglycaemia’ provide valuable addi-
tional information about an individual’s BG control well beyond 
Table 2. Devices for blood/interstitial glucose monitoring: comparison of main features 
Type Description Example(s) of devices Advantagesa Disadvantagesa
Blood glucose (BG) 
meters with inger-
prick testing 
Finger-prick capillary blood 
samples applied to reagent 
test strips 
Multitude of devices from several 
manufacturers 
Availability, price Necessity for frequent 
inger pricking with  
associated discomfort/
pain
BG meters with avail-
ability for ketone 
bodies testing
As above plus availability to 
test for ketone bodies 
(mostly β-hydroxybutyrate) 
FreeStyle® Optium Neo (Abbott 
Diabetes Care), GlucoMen® Areo, 
LX2 or LX PLUS (Menarini  
Diagnostics Ltd.) and others 
As above plus ability to  
detect ketone bodies earlier 
than with urine testing
As above plus higher cost 
of ketonaemia test 
strips in comparison to 
urine test strips
Continuous glucose 
monitoring (CGM)
Subcutaneous sensor  
measures interstitial  
glucose (IG) every 5–10 
min. IG data is then trans-
mitted to a reader with a 
monitor where it can be 
viewed by the user.
Several devices from various  
manufacturers
No need for inger-prick 
testing (apart from  
calibration). More data 
available in comparison to 
BG meters enabling more 
sophisticated data analysis. 
Trends in IG available 
with option of predictive 
alarms
Higher cost in comparison 
to BG meters. 4–10 min 
lag between BG and 
measured IG. Calibra-
tion by the user re-
quired
CGM linked with in-
sulin pumps (CSII)
SAP: CGM data shown on 
CSII monitor
SAP with LGS and Hybrid 
closed-loop system: CGM 
data able to inluence the 
rate of insulin delivery by 
the insulin pump (see the 
text) 
Sensor augmented pump (SAP): 
Animas® VibeTM (Animas Corp.), 
Accu-Chek Insight or Combo 
(Roche Diabetes Care) and  
others. SAP with low  
glucose suspend (LGS):  
MiniMedTM Paradigm VeoTM, 
MiniMedTM 640G (Medtronic 
Inc.) 
Hybrid closed-loop system:  
MiniMedTM 670G (Medtronic 
Inc.)
As above plus steps towards 
‘artiicial pancreas’ with 
SAP, SAP with LGS and 
‘hybrid closed-loop’  
systems
Cost, availability
Flash glucose moni-
toring systems
Similar to CGM, but IG 
data does not get  
automatically transmitted 
to the reader—need for 
swiping
FreeStyle® Libre (Abbott Diabetes 
Care)
Lower cost in comparison 
to CGM. No need for  
calibration
No availability of  
predictive alarms for 
hypo/hyperglycaemia
CSII, continuous subcutaneous insulin infusion. 
aPlease note listed advantages and disadvantages might be perceived by patients on highly individual basis and discussion with patients about 
the most appropriate device is encouraged.
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the HbA1c and the recently published international consensus 
on use of CGM provides guidance of their reporting [58]. 
HYPOGLYCAEMIA
Deinition and epidemiology
Iatrogenic hypoglycaemia continues to remain a major barrier 
in achieving tight glycaemic control in T1DM [59]. he precise 
deinition of hypoglycaemia is, however, debatable. According 
to an ADA working group, symptomatic hypoglycaemia is de-
fined as typical symptoms of hypoglycaemia with a glucose 
measurement of <3.9 mmol/L, whereas SH is deined by the 
need for assistance from another person during an episode 
[60]. here is no clear global consensus on single deinition of 
hypoglycaemia leading to heterogeneity in reporting in both 
observational studies and in clinical trials. his inconsistency 
makes it challenging to directly compare diferent populations. 
Recently, the International Hypoglycaemia Study Group has 
proposed an additional deinition of hypoglycaemia with glu-
cose concentrations <3.0 mmol/L [61]. It is hoped that this 
deinition proposed jointly by the ADA and European Associ-
ation for the Study of Diabetes will be adopted broadly allow-
ing for meaningful comparisons between studies investigating 
the epidemiology of hypoglycaemia and interventions aimed 
at reducing hypoglycaemia.
Studies investigating the epidemiology of hypoglycaemia in 
T1DM are compromised by several limitations. Most studies 
have focused on retrospective patient reported events which 
are prone to recall bias. Where data on hypoglycaemia occur-
rence has been collected prospectively, this has been over brief 
periods of time typically between 30 to 90 days introducing the 
possibility of sampling error. Finally, the populations studied 
have been prone to selection bias as those particularly prone to 
hypoglycaemia were likely to participate. One of the most reli-
able prospective population-based studies has estimated the in-
cidence of SH in T1DM at 1.15 events per person per year [62].
Impaired awareness of hypoglycaemia
It is recognised, that repeated episodes of iatrogenic hypogly-
caemia attenuate the defensive physiological autonomic re-
sponse to subsequent episodes of hypoglycaemia [63]. This 
phenomenon resets the glycaemic threshold for activation of 
counter-regulation to a lower glucose value. Consequently, it 
impairs patient’s ability to perceive the onset of hypoglycaemia 
[64]. No comprehensive deinition of IAH is currently in use 
but Gold et al. [65] and Clarke et al. [66] have proposed scales 
to recognise IAH in T1DM. he prevalence of IAH is estimat-
ed to be as high as 50% in those with T1DM ater 25 years of 
treatment [67].
Morbidity and mortality associated with hypoglycaemia in 
T1DM
Hypoglycaemia is associated with considerable morbidity and 
even mortality in T1DM. It is important to mention; however, 
that the association of hypoglycaemia with increased mortality 
does not necessarily imply causation due to potential con-
founding. Hypoglycaemia might be purely a surrogate marker 
of poor health as it is likely to be more prevalent in renal and 
liver pathologies, which independently increase CV risk [68]. 
In 1991, Tattersall and Gill [69] described the phenomenon of 
sudden unexplained nocturnal death in young people with 
T1DM. his fortunately rare, but tragic event was termed the 
“dead-in-bed” syndrome [70]. It has been hypothesised that 
nocturnal hypoglycaemia can lead to the dead-in-bed syn-
drome via its proarrhythmogenic efects [71-73]. Mechanisms 
through which hypoglycaemia exerts its proarrhythmogenic 
efects include sympathoadrenal activation, hypokalaemia and 
direct inhibition of the rapid delayed rectiier potassium chan-
nels (IKr) in the cardiomyocyte membrane with resulting QT-
interval prolongation [74,75]. he sympathoadrenal response 
to hypoglycaemia can also lead to intracytoplasmic calcium 
overload in cardiomyocytes which is another well-recognised 
proarrhythmogenic trigger [76]. In observational studies, hy-
poglycaemia has been shown to increase the relative risk of 
nocturnal bradycardia in young and otherwise healthy indi-
viduals with T1DM [77], as well as in middle-aged people with 
T2DM and present CV risk factors [78]. Hypopglycaemia has 
been shown to exert a number of efects on inlammation and 
thrombosis that can serve to increase CV risk. Hypoglycaemia 
has been shown to be pro-thrombotic by causing both platelet 
aggregation and activation [79,80] which is likely to be mediat-
ed by the catecholamine response to hypoglycaemia [80]. In 
addition, hypoglycaemia also increases levels of factor VIII, 
von Willebrand factor and impairs thrombolysis [81]. Further-
more, hypoglycaemia promotes a pro-inlammatory milieu by 
inducing an acute leukocytosis [82], increasing levels of the 
pro-inlammatory cytokines tumor necrosis factor D and in-
terleukin 6 and cell adhesion molecules ICAM-1 (intercellular 
adhesion molecule 1), VCAM-1 (vascular cell adhesion mole-
cule 1), and E-selectin [81]. It has also recently been shown 
Iqbal A, et al.
12 Diabetes Metab J 2018;42:3-18 http://e-dmj.org
that repeated episodes of hypoglycaemia may directly damage 
the vascular endothelium in man by impairing nitric oxide 
mediated endothelial function [83]. Fig. 1 summarises the 
mechanisms through which hypoglycaemia may potentially 
increase CV risk.
In addition to adverse biological efects, hypoglycaemia has 
been shown to signiicantly impair quality of life in people with 
T1DM [84]. Negative psychological efects of hypoglycaemia 
are particularly deleterious as they can form a cognitive barrier 
preventing treatment of future episodes and thus impeding the 
treatment of IAH [85].
Structured education programmes in managing 
hypoglycaemia in T1DM
Given the many risks associated with hypoglycaemia various 
advances in T1DM have speciically been aimed at mitigating 
this risk. In addition to new generation insulins and use of 
technology, structured diabetes education programmes are ex-
tremely important interventions that can be deployed in 
T1DM. Programmes aimed at reversing IAH and reducing SH 
are based on the observation that even in long-standing IAH, 
scrupulous avoidance of further hypoglycaemia can restore re-
duced symptomatic and neuroendocrine responses to hypo-
glycaemia [86,87]. he basic premise of structured education/
training programmes in the clinical management of T1DM is 
to allow patients to better self-manage their diabetes by em-
powering them with critical skills. The common features 
amongst various programmes are the use of a ixed curriculum 
and trained educators that focus on intensive BG monitoring 
(including nocturnal testing), carbohydrate counting to allow 
a lexible diet and separation of basal insulin from pre-meal 
bolus insulin. hese fundamental principles are based on the 
Fig. 1. Putative mechanisms linking hypoglycaemia to increased cardiovascular (CV) risk. Hypoglycaemia is characterised by 
sympathoadrenal activation. Abnormal cardiac repolarisation and deranged autonomic function as well as the acute haemody-
namic consequences of hypoglycaemia can induce CV events via arrhythmias (1) and cardiac ischemia (2). Enhanced coagula-
tion and impaired ibrinolysis (3) in addition to platelet activation and aggregation (6) promotes atherothrombosis. Acute leuco-
cytosis and production of pro-inlammatory cytokines (4) as well as upregulation of cell adhesion molecules (5) is likely to en-
courage atherogenesis in an incremental fashion.
Hypoglycaemia
Sympathoadrenal activation
(1) Arrhythmias
(3) Abnormal coagulation (4) Inlammation
(5) Endothelial dysfunction
(6) Platelet activation
(2) Ischemia
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Diabetes Teaching and Treatment Programme (DTTP) that 
was irst delivered over 5 days to inpatients in Germany and 
former Eastern Bloc European countries in the 1980s [39]. he 
authors showed in larger trials that education by way of DTTP 
resulted in improvement of HbA1c in the order of 1.5% to 3% 
at up to 1 year of follow-up with reduced ketoacidosis but no 
change in rates of SH [88,89]. However, a large observational 
study involving 9,583 individuals with T1DM has shown that 
an exponential relationship between the levels of HbA1c and 
risk of SH can be abolished in those that underwent DTTP 
training [90]. In the UK, a 5-day structured education pro-
gramme ‘DAFNE’ modelled on the DTTP was adopted follow-
ing a multi-centre RCT [40]. In the DAFNE cohort, there were 
observed improvements in HbA1c at 6 months compared to 
controls (0.7% to 1%, P<0.0001); however, there was no im-
provement in the incidence of SH, potentially because the trial 
was underpowered to detect this diference [40]. Longer-term 
observational data from a larger number of DAFNE partici-
pants have however demonstrated up to a 50% reduction in 
the rates of SH (mean±SD: pre-DAFNE 1.7±8.5 vs. post-
DAFNE 0.6±3.7 episodes per person-year, P<0.05) in addi-
tion to improved awareness of hypoglycaemia in up to 43% of 
participants at 12 months of follow-up [91]. 
Despite structured education, some people with T1DM con-
tinue to experience signiicant hypoglycaemia or develop IAH. 
hese individuals may have cognitive and psychological barri-
ers that impair their ability to avoid hypoglycaemia [92]. A 
number of structured education interventions termed ‘psycho-
educational’ have been developed to specifically address the 
needs of this population especially in the context of IAH. 
Amongst these, the blood glucose awareness training (BGAT) 
is the most long-standing [93]. In BGAT, participants are 
taught to recognise and appropriately respond to hypoglycae-
mia cues including physical symptoms but also cognitive and 
mood changes. A trained psychologist is part of the education 
team and assesses progress. BGAT has been shown to improve 
detection of hypoglycaemia in IAH and reduce hypoglycaemia 
in those with intact awareness without deteriorating glycaemic 
control [94,95]. he DAFNE-Hypoglycaemia Awareness Res-
toration Training (DAFNE-HART) is a pilot psycho-educa-
tional intervention targeted at those that continue to experi-
ence IAH following DAFNE training [85]. he DAFNE-HART 
intervention has been primarily developed by clinical psychol-
ogists that focus on motivational interviews and cognitive be-
havioural therapy techniques. In 24 individuals with T1DM 
and confirmed IAH (Gold score ≥4), investigators have re-
ported a significant reduction in SH (median [range]: pre-
DAFNE-HART 3 [0 to 104] vs. post-DAFNE-HART 0 [0–3] 
episodes per person-year, P<0.001) and improved awareness 
of hypoglycaemia without a worsening of glycaemic control 
(pre-DAFNE-HART 7.8% [62 mmol/mol] vs. post-DAFNE-
HART 7.8% [61.8 mmol/mol]) at 12 months following inter-
vention [85]. Data from this small pilot study await replication 
in randomized trials with adequate power.
CONCLUSIONS
Significant advances in management of T1DM have been 
made in last decades. his is thanks to novel insulin prepara-
tions, advances in technology (CSII, CGM) and a better un-
derstanding of the physiology behind detrimental effects of 
both hypo- and hyperglycaemia. Despite this, daily manage-
ment of T1DM is a challenging, complex task requiring the 
continuous application of considerable skill on the part of the 
person with the condition. here are very few, if any, medical 
conditions that would require a comparable level of skills, 
knowledge, and understanding than T1DM. With this in 
mind, the role of the healthcare professional (ideally working 
in a multi-disciplinary team) should be supporting individuals 
to achieve the optimal long-term outcomes. his needs to re-
lect individual diferences in circumstances, social and cultur-
al background and own perceptions and goals in relation to 
their condition. 
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